This is a non-core endpoint: only basic statistics are computed.
Follicular adenocarcinoma of thyroid gland
C3_THYROID_FOLLICULAR
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
255 |
4. Check minimum number of eventsNone |
255 |
5. Include endpointsNone |
255 |
6. Filter based on genotype QC (FinnGen only) |
239 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Follicular adenocarcinoma of thyroid gland
based on the number of shared cases.
Similar with more cases:
- Follicular adenocarcinoma of thyroid gland, including Hilmo
- Malignant neoplasm of thyroid gland
- Malignant neoplasm of endocrine gland
- Malignant neoplasm of thyroid gland, including Hilmo
- Malignant neoplasm of endocrine gland, including Hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 239 | 148 | 91 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | 52.56 | 48.03 | 59.92 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 247
- Matched controls
- 2470
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8330/3-C73.9
ICD-O-3
Follicular carcinoma, NOS, of thyroid gland
+∞
323.3
234
*
C73.92
ICD-10 Finland
Follicular carcinoma of the thyroid gland
+∞
282.8
214
*
104
Kela drug reimbursment
Thyroid insufficiency
74.6
266.1
187
99
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
131.8
245.8
128
20
EP1AE
NOMESCO Finland
Neck ultrasound examination
54.7
194.6
123
44
H03AA01
ATC
levothyroxine sodium; systemic
102.0
171.0
235
398
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
68.7
129.9
73
15
BAA60
NOMESCO Finland
Total thyroidectomy
59.5
119.3
69
16
XX7CT
NOMESCO Finland
Radioiodine therapy of thydoid tissue
834.7
111.1
101
*
D44.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thyroid gland
396.3
103.3
97
*
JN5PN
NOMESCO Finland
Isotope imaging of secondary neoplasms of thyroid origin
+∞
87.9
79
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
83.1
75
*
E04.2
ICD-10 Finland
Nontoxic multinodular goitre
14.7
52.2
51
43
C73
ICD-10 Finland
Malignant neoplasm of thyroid gland
+∞
47.4
44
*
JN5AQ
NOMESCO Finland
SPECT of thyroid metastasis with low-dose CT
+∞
45.2
42
*
130
Kela drug reimbursment
Malignant tumour
+∞
41.9
39
*
ZX114
NOMESCO Finland
Intramuscular
59.1
38.1
44
9
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.2
36.7
151
573
E04.1
ICD-10 Finland
Nontoxic single thyroid nodule
41.8
34.1
42
12
C73.99
ICD-10 Finland
Malignant tumor of the thyroid gland (thyroid gland), other or unspecified histology
+∞
29.8
28
*
C73.90
ICD-10 Finland
Malignant tumor of the thyroid gland (thyroid gland) without histology
+∞
28.7
27
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.3
28.7
119
436
4CJ01, ,
NOMESCO Finland
+∞
27.6
26
*
BA1NN
NOMESCO Finland
I-131 dose capsel measurement
+∞
26.5
25
*
BA3AT
NOMESCO Finland
Cytology of thyroid with ultrasound quidance
30.1
25.7
34
13
19399
ICD-8 Finland
Malignant neoplasm of thyroid gland
+∞
24.4
23
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
264.6
24.1
24
*
JN4AD
NOMESCO Finland
Body CT examination
6.8
22.4
38
64
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
22.2
21
*
Z51.5
ICD-10 Finland
Palliative care
8.6
22.2
30
39
XX3DW
NOMESCO Finland
Time consuming IT work
6.9
20.4
34
56
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
20.1
19
*
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
29.3
18.2
24
9
D34
ICD-10 Finland
Benign neoplasm of thyroid gland
72.2
18.0
20
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
17.9
17
*
WX402
NOMESCO Finland
General anaesthesia
3.6
17.8
75
265
E04.9
ICD-10 Finland
Nontoxic goitre, unspecified
16.7
17.1
27
18
H02AB02
ATC
dexamethasone; systemic
25.2
16.8
23
10
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
14.7
14
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
14.7
14
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
14.7
14
*
1930B
ICD-9 Finland
Malignant neoplasm of thyroid gland[CARCINOMA FOLLICULARE THYREOIDEAE]
+∞
13.7
13
*
8335/3-C73.9
ICD-O-3
Follicular carcinoma, minimally invasive of thyroid gland
+∞
13.7
13
*
PJ3AT
NOMESCO Finland
Cytology of lymphnode with ultrasound guidance
147.8
13.6
14
*
Z51.88
ICD-10 Finland
Other specified medical care
12.0
13.3
24
22
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
+∞
12.6
12
*
WW200
NOMESCO Finland
Immunization
11.4
12.0
22
21
WF002
NOMESCO Finland
Radical radiotherapy
49.2
12.0
14
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
68.3
11.7
13
*
E89.09
ICD-10 Finland
Postprocedural hypothyroidism, other or several procedures
+∞
11.5
11
*
T71
ICPC
Malignant neoplasm thyroid
+∞
11.5
11
*
115
Kela drug reimbursment
Breast cancer
+∞
11.5
11
*
A04AA02
ATC
granisetron; systemic, transdermal
125.6
11.5
12
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
11.0
104
553
106
Kela drug reimbursment
Hypoparathyroidism
+∞
10.5
10
*
JN4BD
NOMESCO Finland
Extensive body CT
5.1
10.5
23
49
JN6AD
NOMESCO Finland
CT of torso and neck
24.6
10.4
14
6
2506
FHL
Thyroidectomy
+∞
9.4
9
*
116
Kela drug reimbursment
Prostate cancer
+∞
9.4
9
*
E89.2
ICD-10 Finland
Postprocedural hypoparathyroidism
+∞
9.4
9
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
9.4
9
*
JN5SN, ,
NOMESCO Finland
+∞
9.4
9
*
N02AA05
ATC
oxycodone; systemic
2.9
9.4
52
210
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.7
9.3
57
243
BA1AE
NOMESCO Finland
Thyroiid ultrasound examination
11.3
8.9
16
15
NK6AN
NOMESCO Finland
Total body bone isotope imaging
51.9
8.7
10
*
A03FA01
ATC
metoclopramide; systemic, rectal
2.8
8.7
48
193
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
93.1
8.5
9
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
8.4
8
*
PJD71
NOMESCO Finland
Extended sparing excision of cervical lymph nodes
+∞
8.4
8
*
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
+∞
8.4
8
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
8.4
8
*
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
+∞
8.4
8
*
GD6AD
NOMESCO Finland
CT of chest and neck
34.6
8.1
10
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
34.6
8.1
10
*
XW1AT
NOMESCO Finland
Biopsy from other organ close to skin with ultrasound quidance
22.9
8.1
11
5
WX704
NOMESCO Finland
Intubation
3.8
8.1
26
75
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
8.2
8.0
17
22
HA1AA
NOMESCO Finland
X-ray mammography
4.8
7.8
18
40
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
46.5
7.8
9
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
82.5
7.5
8
*
A11CC03
ATC
alfacalcidol; systemic
8.8
7.4
15
18
198
Kela drug reimbursment
Sorafenib
+∞
7.3
7
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.3
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.3
7
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
7.3
7
*
1508
Kela drug reimbursment
Lenvatinib
+∞
7.3
7
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
7.3
7
*
3019
Kela drug reimbursment
Lenvatinib
+∞
7.3
7
*
323
Kela drug reimbursment
Sorafenib
+∞
7.3
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.3
7
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.7
7.3
17
38
WZC30
NOMESCO Finland
Teaching
2.7
7.2
41
167
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
7.1
66
340
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
17.3
6.8
10
6
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
+∞
6.3
6
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
6.3
6
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.4
6.2
23
73
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
23
38.79
102.03
1.4
1.2
—
—
—
0
0
198
1011
5.83
31.21
13.4
6.0
1.20
1.21
mmol/l
1.09
160
885
184
915
4.96
29.21
10.1
5.5
1.21
1.21
mmol/l
0.96
174
834
68
166
5.27
27.40
2.3
4.1
46.42
82.53
ng/l
6.61
57
145
148
699
3.79
23.51
5.0
2.0
2.30
2.36
mmol/l
5.14
141
609
31
40
8.72
23.08
2.2
2.8
4.56
11.87
pmol/l
2.11
31
40
228
1651
5.95
15.58
14.0
4.4
17.88
14.82
pmol/l
30.89
218
1511
148
905
2.59
11.88
2.9
2.3
—
—
estimate
—
0
0
24
51
5.10
10.97
2.1
2.2
2.22
6.28
iu/l
—
10
24
138
877
2.30
9.36
5.6
3.7
36.53
36.01
g/l
0.59
128
820
46
197
2.64
7.36
3.7
3.2
—
—
—
0
0
139
971
1.99
6.48
3.0
2.6
78.67
77.84
nmol/l
0.14
130
862
197
1563
2.29
6.47
10.9
5.5
75.43
75.72
u/l
0.05
187
1457
154
1119
2.00
6.36
8.7
6.5
4.11
4.17
e9/l
0.13
134
963
28
99
3.06
6.34
3.7
1.5
2.52
2.77
ug/l
0.13
21
77
6
0
+∞
6.27
1.0
0.0
15.17
—
u/ml
—
6
0
229
1957
3.33
6.27
19.3
5.4
3.30
1.90
mu/l
0.56
219
1810
166
1247
2.01
6.13
4.9
4.3
6.42
6.69
mmol/l
1.09
156
1170
143
1047
1.87
5.41
7.7
3.8
10.76
11.51
umol/l
0.67
135
989
76
465
1.92
4.96
2.4
1.9
—
—
—
0
0
93
619
1.81
4.60
4.8
3.9
0.00
0.00
estimate
-0.00
41
198
94
629
1.80
4.56
4.5
3.2
0.00
0.00
estimate
-0.00
38
175
31
150
2.22
3.77
1.2
1.3
56.21
117.71
u/ml
0.90
12
64
47
268
1.93
3.71
4.0
5.2
1.08
1.05
mmol/l
0.40
41
237
103
741
1.67
3.69
2.8
3.2
—
—
—
0
0
9
17
5.45
3.54
1.3
1.5
—
—
—
0
0
116
869
1.63
3.50
4.9
3.6
0.00
0.00
estimate
-0.00
37
168
15
54
2.89
3.32
4.4
3.9
—
—
—
0
0
81
588
1.56
2.64
2.7
3.0
0.32
0.44
e6/l
0.41
64
424
5
7
7.26
2.56
7.8
3.1
3.68
5.87
nmol/l
—
5
7
225
2072
1.96
2.42
22.5
13.6
21.71
22.53
mg/l
0.14
182
1660
76
995
0.66
2.36
2.2
2.1
92.28
97.65
pmol/l
0.61
47
508
111
881
1.47
2.31
4.3
3.9
20.66
45.29
ng/l
2.49
77
625
8
23
3.56
2.29
1.4
1.1
—
—
—
0
0
6
13
4.70
2.28
2.2
1.2
—
—
—
0
0
11
41
2.76
2.24
1.5
1.1
—
—
—
0
0
5
9
5.64
2.22
1.6
1.7
14.16
15.32
ug/l
—
5
9
21
115
1.90
1.89
6.1
4.3
3.66
1.96
mmol/l
0.86
16
83
134
1131
1.40
1.88
4.6
3.8
0.00
0.00
estimate
-0.00
42
211
135
1149
1.39
1.76
4.8
3.8
0.00
0.00
estimate
-0.00
44
217
6
18
3.39
1.75
1.3
1.1
—
—
—
0
0
136
1161
1.38
1.73
4.8
3.9
0.00
0.02
estimate
0.50
42
201
10
40
2.56
1.68
1.0
1.4
—
—
—
0
0
10
40
2.56
1.68
2.0
1.3
53.60
62.13
pmol/l
—
10
40
10
40
2.56
1.68
1.0
1.4
—
—
—
0
0
5
14
3.62
1.62
1.6
1.1
—
—
—
0
0
6
20
3.05
1.59
1.2
1.1
—
—
—
0
0
225
2119
1.69
1.57
23.6
16.7
3.95
3.97
mmol/l
0.68
219
2075
33
219
1.59
1.56
3.3
6.7
0.98
1.18
mmol/l
0.15
25
183
225
2120
1.69
1.55
23.0
16.6
139.83
139.75
mmol/l
0.20
220
2077
5
15
3.38
1.53
1.2
1.1
—
—
—
0
0
47
340
1.47
1.51
2.5
1.7
—
—
—
0
0
61
775
0.72
1.44
5.5
3.9
21.58
7.70
mg/mmol
0.70
36
480
13
67
1.99
1.41
4.0
2.8
26.43
24.38
mmol/l
0.94
13
67
9
41
2.24
1.38
1.7
1.1
—
—
—
0
0
22
138
1.65
1.31
6.7
4.1
5.41
5.09
kpa
1.32
22
133
213
2004
1.46
1.23
22.4
12.8
80.95
80.03
ml/min/173m2
0.25
202
1838
15
89
1.73
1.10
4.7
3.7
1.59
1.58
%
0.03
15
84
5
21
2.41
1.09
1.2
1.0
—
—
—
0
0
57
454
1.33
1.06
1.7
1.8
421.27
445.20
pmol/l
0.25
45
375
7
33
2.15
1.06
1.1
1.3
—
—
—
0
0
17
261
0.63
1.06
4.5
5.2
31.56
32.47
%
—
9
165
19
124
1.58
1.00
2.9
5.4
24.29
25.18
mmol/l
0.83
19
118
18
116
1.60
0.99
1.4
1.4
—
—
—
0
0
35
458
0.73
0.97
4.1
3.9
493.38
330.12
ng/l
0.14
26
364
34
253
1.40
0.97
7.8
6.7
—
—
—
0
0
6
28
2.17
0.92
1.7
1.1
—
—
—
0
0
8
43
1.89
0.88
1.5
1.1
—
—
—
0
0
6
33
1.84
0.79
1.7
1.1
—
—
—
0
0
65
551
1.24
0.76
5.8
4.0
2.44
1.90
ug/l
0.59
58
499
53
440
1.26
0.74
4.5
3.7
20.21
24.58
%
1.53
26
206
5
25
2.02
0.73
1.6
2.0
3.26
153.57
u/ml
—
5
25
5
25
2.02
0.73
1.0
3.2
—
14.66
—
0
8
170
1592
1.22
0.71
4.4
4.3
13.37
11.70
mm/h
0.53
156
1479
7
41
1.73
0.70
1.1
1.3
—
—
—
0
0
7
41
1.73
0.70
3.0
2.0
4.00
16.35
u/ml
—
7
34
78
682
1.21
0.68
2.4
2.2
92.52
55.40
u/l
0.54
67
635
7
43
1.65
0.67
1.3
1.5
—
—
—
0
0
83
932
0.84
0.65
2.2
1.9
1.42
1.36
mmol/l
0.30
63
793
62
533
1.22
0.63
5.5
3.8
1.02
1.02
kg/l
0.71
42
338
9
140
0.63
0.62
1.3
1.4
—
36.85
—
0
13
11
72
1.55
0.60
2.5
1.7
0.30
1.33
ug/l
1.54
11
63
31
248
1.29
0.59
1.9
1.7
—
—
—
0
0
6
36
1.68
0.57
1.2
1.0
—
—
—
0
0
9
61
1.49
0.54
1.3
1.2
—
—
—
0
0
225
2190
1.31
0.53
14.3
9.8
24.18
25.23
u/l
0.59
220
2127
32
261
1.26
0.53
2.0
1.7
—
—
—
0
0
63
553
1.19
0.52
2.6
2.4
3.78
2.79
mg/l
1.81
56
469
29
237
1.25
0.48
1.7
2.6
4.63
6.17
umol/l
1.46
22
208
36
302
1.22
0.48
1.8
2.0
28.96
29.50
s
0.27
36
291
16
209
0.75
0.47
1.6
2.1
3.55
3.27
ratio
—
8
172
5
85
0.58
0.46
2.2
1.7
—
—
—
0
0
9
128
0.69
0.44
1.2
1.3
—
—
—
0
0
8
57
1.42
0.42
1.5
1.2
—
—
—
0
0
37
316
1.20
0.42
4.0
2.7
0.77
0.78
ug/l
0.02
24
201
48
544
0.85
0.41
1.3
1.3
1.49
1.49
u/ml
0.00
17
145
8
60
1.34
0.40
2.6
1.8
—
—
—
0
0
10
71
1.43
0.40
1.0
1.1
1.36
1.58
g/l
—
10
71
13
170
0.75
0.39
1.4
1.4
—
—
—
0
0
5
35
1.44
0.39
2.2
1.5
—
—
—
0
0
10
72
1.41
0.37
1.0
1.2
0.95
0.87
g/l
—
10
72
5
37
1.36
0.37
1.0
1.4
—
—
—
0
0
10
132
0.75
0.33
2.6
2.2
—
—
—
0
0
10
74
1.37
0.33
9.7
5.0
27.07
24.87
mmol/l
—
10
67
12
152
0.78
0.30
1.2
1.2
218.92
456.26
u/ml
0.47
12
144
10
130
0.76
0.30
1.0
1.1
—
—
—
0
0
7
56
1.26
0.29
1.1
1.3
—
—
—
0
0
8
108
0.73
0.29
2.5
2.2
—
—
—
0
0
21
248
0.83
0.29
2.8
2.2
—
—
—
0
0
58
531
1.12
0.28
3.0
2.4
373.88
348.13
umol/l
0.92
49
472
9
119
0.75
0.28
3.2
1.7
—
—
—
0
0
76
709
1.10
0.27
3.4
3.2
946.95
1561.13
ng/l
2.22
65
598
201
2053
0.89
0.26
4.9
5.1
1.43
1.49
mmol/l
1.20
188
1916
5
74
0.67
0.26
1.2
1.4
—
—
—
0
0
9
73
1.24
0.25
5.4
1.6
—
—
—
0
0
39
430
0.89
0.24
1.2
1.4
20.49
38.58
iu/ml
1.81
14
137
26
228
1.16
0.24
2.3
3.5
2.16
1.64
mmol/l
0.44
20
197
44
401
1.12
0.23
1.8
1.7
—
—
—
0
0
5
40
1.26
0.22
1.6
1.6
—
—
—
0
0
45
489
0.90
0.22
1.5
1.7
0.84
1.15
mg/l
0.77
36
373
0
11
0.00
0.21
0.0
1.1
—
17.09
—
0
11
0
11
0.00
0.21
0.0
1.2
—
384.73
—
0
11
0
11
0.00
0.21
0.0
1.0
—
41.05
—
0
11
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
375.80
—
0
5
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
203
2066
0.90
0.21
5.1
5.2
4.61
4.60
mmol/l
0.06
189
1940
10
123
0.81
0.21
1.4
2.7
0.90
1.21
%
—
10
123
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
50
1.20
0.20
1.0
1.4
—
—
—
0
0
10
122
0.81
0.19
1.4
2.7
0.57
0.60
%
—
10
122
195
1985
0.92
0.19
6.4
6.6
39.30
39.41
mmol/mol
0.06
180
1870
7
59
1.19
0.18
1.7
1.2
—
—
—
0
0
34
370
0.91
0.17
2.3
1.8
1281.28
1229.26
nmol/l
0.10
26
284
8
69
1.16
0.16
5.3
1.6
—
—
—
0
0
14
161
0.86
0.15
1.3
1.9
3.58
3.36
mmol/l
—
5
126
37
398
0.92
0.15
1.3
1.3
37.36
11.51
u/ml
0.55
13
149
16
141
1.14
0.14
2.1
1.4
—
—
—
0
0
17
152
1.13
0.12
3.8
2.1
68.09
69.32
ml/min/173m2
0.05
11
66
193
1955
0.94
0.11
4.1
4.4
1.37
1.25
mmol/l
1.62
178
1801
5
60
0.83
0.08
1.8
1.7
234.80
323.03
mu/l
—
5
54
144
1417
1.04
0.08
3.4
3.2
41.43
42.56
u/l
0.10
127
1338
7
68
1.03
0.08
1.1
1.8
0.21
0.22
g/l
—
7
68
33
344
0.95
0.05
1.9
3.0
3.18
3.22
e6/l
0.01
15
155
21
221
0.95
0.04
2.4
2.1
—
—
—
0
0
128
1266
1.02
0.04
3.4
3.1
—
—
—
0
0
65
659
0.98
0.02
1.7
1.7
19.88
20.19
nmol/l
0.06
60
557
100
992
1.01
0.01
3.6
3.1
97.58
105.62
ug/l
0.25
92
919
20
206
0.97
0.00
1.9
2.5
4.74
6.02
ug/l
0.18
15
176
205
2044
1.02
0.00
4.8
5.1
5.91
5.95
mmol/l
0.17
187
1877
210
2098
1.01
0.00
5.6
6.0
2.71
2.67
mmol/l
0.29
195
1965
37
367
1.01
0.00
1.9
2.8
1.85
1.15
e6/l
0.39
19
177
34
335
1.02
0.00
1.5
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
213.63
—
0
8
0
5
0.00
-0.00
0.0
2.2
—
1.40
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
67
0.89
-0.00
1.2
1.5
—
—
—
0
0
7
69
1.01
-0.00
1.1
1.8
1.09
1.14
g/l
—
7
69
0
9
0.00
-0.00
0.0
1.1
—
10.78
—
0
9
16
160
1.00
-0.00
2.5
3.9
285.09
274.76
ng/l
0.02
16
145
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_THYROID_FOLLICULAR – Follicular adenocarcinoma of thyroid gland
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).